Expanding Access and Optimizing the Use of CAR T-Cell Therapy in Multiple Myeloma

Panelists discuss how pivotal trials and real-world evidence have reinforced CAR T-cell therapy’s high response rates, deep remissions, and durable outcomes in relapsed/refractory multiple myeloma.

Panelists discuss how differences in BCMA-directed CAR T constructs (including binding configuration and expansion kinetics) can influence toxicity timing, monitoring needs, and real-world product selection.

Panelists discuss how clinicians distinguish candidates for second-line versus third-line CAR T by weighing disease aggressiveness, relapse timing, cytogenetic risk, patient preferences, and toxicity tradeoffs.

Panelists discuss how prior BCMA-directed or bispecific therapy may affect T-cell fitness and CAR T planning, including the value of early referral and strategic washout/bridging approaches when feasible.

Panelists discuss how sequencing choices before third-line CAR T balance disease control and eligibility preservation, while avoiding prolonged therapies that could compromise later collection or outcomes.

Panelists discuss how real-world CAR T outcomes in older or comorbid patients can mirror trial results when organ function, monitoring, and multidisciplinary support are optimized.

Panelists discuss how early referral drop-off is driven by awareness gaps, outdated perceptions of when CAR T should be used, travel/caregiver burdens, and process complexity—and which barriers are most addressable.